More on PFE

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+14.3% Growth)
- Ratings (5.8 Score)
- Holders
- Dividends (3.5% Yield)
- Event Driven Deals

Financials

Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (10/27/16 *Est.)
- Ex-Dividend (11/8/2016)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

PFE Income Statement

Click line-items for a historical chart and %
Revenues
Costs and expenses:
Cost of sales
Selling, informational and administrative expenses 3.47B
Research and development expenses 1.75B
Amortization of intangible assets
Acquisition-related in-process research and development charges
Restructuring charges and certain acquisition-related costs 316M
Other deductions--net
Income from continuing operations before provision for taxes on income 2.41B
Provision for taxes on income 375M
Income from continuing operations 2.04B
Discontinued operations:
Income from operations--net of tax
Gain on sale of discontinued operations--net of tax
Discontinued operations--net of tax 1M
Net income before allocation to noncontrolling interests 2.04B
Less: Net income attributable to noncontrolling interests 16M
Net income attributable to Pfizer Inc. 2.02B
Earnings per share--basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders 0.33
Discontinued operations--net of tax (in dollars per share) 0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) 0.33
Earnings per share--diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) 0.33
Discontinued operations--net of tax (in dollars per share) 0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) 0.33
Weighted-average shares used to calculate earnings per common share:
Basic (in shares) 6.07B
Diluted (in shares) 6.14B
Cash dividends paid per common share (in dollars per share) 0.3